Vascular calcification inhibitors in relation to cardiovascular disease with special emphasis on fetuin-A in chronic...

Area of Science:

• Nephrology
• Cardiovascular Medicine
• Biochemistry

Background:

• Chronic kidney disease (CKD) is associated with high mortality, primarily due to cardiovascular disease (CVD).
• Nontraditional risk factors including inflammation, oxidative stress, endothelial dysfunction, and vascular calcification contribute to CVD risk in CKD.
• Mineral metabolism disturbances, particularly calcium (Ca) and phosphate (PO4) ions, are linked to accelerated vascular calcification.

Purpose of the Study:

• To investigate the role of circulating calcification mediators in CKD-related vascular complications.
• To highlight fetuin-A (alpha 2-Heremans-Schmid glycoprotein, AHSG) as a key factor in CKD-associated vascular calcification and mortality.

Main Methods:

• Review of current literature on calcification promoters and inhibitors in CKD.
• Analysis of clinical studies linking fetuin-A levels to vascular calcification and mortality outcomes.
• Exploration of potential mechanisms for fetuin-A depletion and its association with insulin resistance and metabolic syndrome.

Main Results:

• An imbalance of circulating calcification factors (fetuin-A, MGP, OPG, OPN, BMPs, PPi) contributes to vascular tissue deterioration.
• Fetuin-A deficiency is consistently associated with increased vascular calcification, all-cause, and cardiovascular mortality in CKD patients.
• Chronic inflammation, the uremic environment, and AHSG gene mutations may lead to fetuin-A depletion.

Conclusions:

• Imbalances in vascular calcification mediators significantly contribute to CVD prevalence in CKD.
• Fetuin-A plays a critical role in preventing vascular calcification and reducing mortality in CKD.
• Further research into fetuin-A's role in CKD, insulin resistance, and metabolic syndrome is warranted.